Design and rationale of the INSYTE study: a randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal …

E Scorletti, PR Afolabi, EA Miles, DE Smith… - Contemporary clinical …, 2018 - Elsevier
Background Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of fat-related
conditions ranging from simple fatty liver, to non-alcoholic steatohepatitis (NASH), fibrosis …

Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease

E Scorletti, PR Afolabi, EA Miles, DE Smith… - Gastroenterology, 2020 - Elsevier
Background & Aims Dysbiosis of the intestinal microbiota has been associated with
nonalcoholic fatty liver disease (NAFLD). We investigated whether administration of a …

[HTML][HTML] Gut microbiome–targeted therapies in nonalcoholic fatty liver disease: A systematic review, meta-analysis, and meta-regression

SR Sharpton, B Maraj, E Harding-Theobald… - The American journal of …, 2019 - Elsevier
Background Preclinical evidence suggests that modulation of the gut microbiome could
represent a new therapeutic target in nonalcoholic fatty liver disease (NAFLD). Objectives …

Use of probiotics, prebiotics, and synbiotics in non‐alcoholic fatty liver disease: A systematic review and meta‐analysis

L Rong, D Ch'ng, P Jia, KKF Tsoi… - Journal of …, 2023 - Wiley Online Library
Abstract Background and Aim Patients with non‐alcoholic fatty liver disease (NAFLD) exhibit
compositional changes in their gut microbiome, which represents a potential therapeutic …

Efficacy of probiotics and synbiotics in patients with nonalcoholic fatty liver disease: a meta-analysis

L Liu, P Li, Y Liu, Y Zhang - Digestive diseases and sciences, 2019 - Springer
Abstract Background and Aim Extensive epidemiological evidence suggests that
nonalcoholic fatty liver disease (NAFLD) is the primary chronic liver disease worldwide …

[HTML][HTML] Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol

JE Lambert, JA Parnell, B Eksteen, M Raman… - BMC …, 2015 - Springer
Background Evidence for the role of the gut microbiome in the pathogenesis of non-
alcoholic fatty liver disease (NAFLD) is emerging. Strategies to manipulate the gut …

Can bugs be drugs? The potential of probiotics and prebiotics as treatment for non‐alcoholic fatty liver disease

N Koopman, A Molinaro, M Nieuwdorp… - Alimentary …, 2019 - Wiley Online Library
Background Non‐alcoholic fatty liver disease (NAFLD) has become the most common
chronic liver condition. A major current research effort is ongoing to find potential strategies …

[HTML][HTML] Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease

SM Ferolla, GN de Almeida Armiliato… - World journal of …, 2015 - ncbi.nlm.nih.gov
Nonalcoholic fatty liver disease (NAFLD) is currently recognized as one of the most common
causes of chronic liver disease. It involves a spectrum of conditions that include pure …

[HTML][HTML] The therapeutic implications of the gut microbiome and probiotics in patients with NAFLD

BJ Perumpail, AA Li, N John, S Sallam, ND Shah… - Diseases, 2019 - mdpi.com
Recent breakthrough in our understanding pertaining to the pathogenesis of nonalcoholic
fatty liver disease (NAFLD) has pointed to dysregulation or derangement of the gut …

emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications

S Jayakumar, R Loomba - Alimentary pharmacology & …, 2019 - Wiley Online Library
Background Nonalcoholic fatty liver disease (NAFLD) is a prevalent disorder associated with
obesity and diabetes. Few treatment options are effective for patients with NAFLD, but …